Mortality risk in osteoarthritis patients: a meta-analysis of observational studies

骨关节炎患者的死亡风险:一项观察性研究的荟萃分析

阅读:1

Abstract

OBJECTIVES: This study aimed to evaluate the relationship between osteoarthritis (OA) and all-cause mortality, as well as cause-specific mortality. METHODS: This study was registered with PROSPERO (ID: CRD42024542643). A comprehensive literature search was conducted using Medical Subject Headings (MeSH) and keywords across PubMed, Embase, and the Cochrane Library databases, from inception to May 16, 2024. Study quality was assessed using the Newcastle-Ottawa Scale (NOS) and the Agency for Healthcare Research and Quality (AHRQ) criteria. Funnel plots and Egger’s test were used to assess publication bias. Statistical analyses were performed using STATA software version 14.0. RESULTS: Twenty-four observational studies (2003–2023) involving 465,555 OA patients were included. The pooled analysis revealed no significant association with all-cause mortality based on pooled estimates, although with very high heterogeneity [OR = 1.14, 95% CI (0.97, 1.35), I² = 98.2%, P = 0.119], but appeared to be associated with increased (CVD) mortality [OR = 1.15, 95% CI (1.07, 1.24), I² = 73.5%, P < 0.001]. There was no increased risk of cancer mortality [OR = 1.02, 95% CI (0.94, 1.11), I² = 69.4%, P = 0.000]. Subgroup analysis indicated no significant gender-based differences in all-cause mortality, nor in radiographic OA. However, symptomatic OA and knee/foot OA were associated with a markedly higher risk of all-cause mortality. Regional analysis showed no significant variation across Europe, Asia, or North America. Sensitivity and subgroup analyses confirmed the results, with no evidence of publication bias. CONCLUSIONS: This meta-analysis suggests that osteoarthritis is not associated with all-cause mortality but is but is associated with a modest increase in CVD mortality. There is no relationship between OA and cancer mortality. These findings emphasize the importance of focused care and lifestyle modifications to mitigate cardiovascular risks in OA patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-025-09321-4.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。